New drugs in colorectal cancer: A review of antitumor activity and cross-resistance patterns of topoisomerase I inhibitors, thymidylate synthetase inhibitors, and oxaliplatin

Onkologie

Volumn 21, Issue 2, 1998, Pages 95-103

  Harstrick, A ^a   Vanhoefer, U ^a   Seeber, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Colon cancer; Irinotecan; Oxaliplatin; Tomudex; Topoisomerase I Inhibitors

Indexed keywords

9 AMINOCAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NOLATREXED; OXALIPLATIN; PEMETREXED; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CROSS RESISTANCE; HUMAN; REVIEW; TREATMENT OUTCOME;

EID: 7144257872     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026804     Document Type: Review

References (76)

1. Miller BA, Gloeckler LA, Hamkaiy WF, Miller BA, Ries LAG, Hankey BF, Korsary CL, Edwards BK: Cancer Statistics Review 1973-1989 Bethesda. MD, US Department of Health and Human Services, 1992.
2. Ziegler RG, Devesa SS, Fraumeni JF Jr: Epidemiologic patterns of colorectal cancer; in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, Lippincott, 1986, pp 209-232.
3. Howe GR, Benito E, Castelleto R, Cornée J, Estève J, Gallagher RP, Iscovich JM, Deng-ao J, Kaaks R, Kune GA, Kune S, L'Abbé KA, Lee HP, Lee M, Miller AB, Peters RK, Potter JD, Riboli E, Slattery ML, Trichopoulos D, Tuyns A, Tzonou A, Whittemore AS, Wu-Williams AH, Shu Z: Dietary intake of fiber and decreased risks of cancers of the colon and rectum: Evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst 1992;84: 1887-1896.
4. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352-358
5. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer Lancet 1995;345:939-944.
6. Kemeny N: Chemotherapy for colorectal carcinoma: One small step forward, one step backward. J Clin Oncol 1995;13:1287-1290
7. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld M: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-1418.
8. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
9. Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM, Megibow A, Greenwald ES, Bukowski RM, Harris J, Levin B, Gaynor E, Loutfi A, Kalser MH, Barkin JS, Benedetto P, Woolley PV, Nauta R, Weaver DW, Leichman LP. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 1989;7:1419-1426.
10. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, Macdonald JS: Phase II study of fluorouracil and its modulation in advanced colorectal cancer A Southwest Oncology Group study. J Clin Oncol 1995;13:1303-1311.
11. Corfu-A Study Group: Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995;13:921-928.
12. Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M, Hickish T: Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 1995;13 1297-1302.
13. Raderer M, Scheithauer W: Treatment of advanced colorectal cancer with 5-fluorouracil and interferon alpha: An overview of clinical trials. Eur J Cancer 1995;31:1002-1008
14. Evans RM, Laskin JD, Hakala MT: Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells Cancer Res 1980; 40:4113-4122.
15. Santelli G, Valeriote F: Schedule-dependent cytotoxicity of 5-fluorouracil in mice. J Natl Cancer Inst 1986;76:159-164.
16. Santi DV, McHenry CS, Sommer H Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974;13 471-480.
17. 10-propargyl-5,8-dideazafolic acid (CB3717). Natl Cancer Inst Monogr 1987;5:213-218.
18. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 1991;51:5579-5586.
19. Duch DS, Banks S, Dev IK, Dickerson SH, Ferone R, Heath LS, Humphreys J, Knick V, Pendergast W, Singer S, Smith GK, Waters K, Wilson HR: Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 1993;53:810-818.
20. Ferone R, Hanlon MH, Waters KA, Dev IK: Influence of intracellular polyglutamation on the cytotoxicity of the thymidylate synthase inhibitor 1843U89. Proc Am Assoc Cancer Res 1993;34:274 (abstract 1630)
21. Webber S, Bartlett CA, Boritzki TJ, Hilliard JA, Howland EF, Johnston AL, Kosa M, Margosiak SA, Morse CA, Shetty BV AG337, a novel lipophilic thymidylate synthase inhibitor. In vitro and in vivo preclinical studies Cancer Chemother Pharmacol 1996;37:509-517.
22. O'Connor BM, Webber S, Jackson RC, Galivan J, Rhee MS: Biological activity of a novel rationally designed lipophilic thymidylate synthase inhibitor. Cancer Chemother Pharmacol 1994;34 225-229.
23. Aschele C, Sobrero A, Faderan MA: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992;52:1855-1864.
24. Harstrick A, Gonzales A, Hoffmann A, Schleucher N, Vanhoefer U, Rustum Y, Seeber S, Wilke H: Development and characterisation of human gastric, colon and breast carcinoma cell lines resistant to 5-FU using various, clinically relevant application schedules. Proc Am Assoc Cancer Res 1995;36:317 (abstract 1889).
25. Jackman AL, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne GW, Hardcastle A, Boyle FT: Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (tomudex) in one mouse and three human cell lines. Br J Cancer 1995;71:914-924.
26. Johnston PG, Behan KA, Allegra CJ, Drake JC: Fluorouracil: Active in ZD1694 (tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels. J Natl Cancer Inst 1995;87 1558-1559.
27. Lu K, Yin MB, McGuire JJ, Bonmassar E, Rustum YM: Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2- thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcimoma cell line. Biochem Pharmacol 1995;50:391-398.
28. Pommier Y Eukaryotic DNA topoisomerase I: Genome gatekeeper and its intruders, camptothecins. Semin Oncol 1996;23(suppl 3) 3-10
29. Chen AY, Liu LF. DNA topoisomerases: Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994;34:191-218
30. Liu LF: DNA topoisomerase poisons as antitumor drugs Annu Rev Biochem 1989;58:351-375.
31. Ryan AJ, Squires S, Strutt HL, Johnson RT: Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 1991;19:3295-3300.
32. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK: Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 1990;38: 471-480.
33. Kapoor R, Slade DL, Fujimori A, Pommier Y, Harker WG: Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol Res 1995;7:83-95.
34. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y, Okada K: Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 1987; 84:5565-5569.
35. Gromova H, Kjeldsen E, Svejstrup JQ, Alsner J, Christiansen K, Westergaard O: Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I Nucleic Acids Res 1993;21 593-600
36. Benedetti P, Fiorani P, Capuani L, Wang JC: Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine Cancer Res 1993;53:4343-4348
37. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F104864), a new camptothecin analogue. Cancer Res 1992;52:2268-2278.
38. Mattern MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL, Johnson RK: In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 1993; 5:467-474.
39. Boudny V, Vrána O, Gaucheron F, Kleinwachter V, Leng M, Brabec V: Biophysical analysis of DNA modified by 1,2-diaminocyclonexane-platinum(II) complexes. Nucleic Acids Res 1992;20:267-272
40. Jennerwein MM, Eastman A, Khokhar AR: Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. Chem Biol Interact 1989;70:39-49.
41. Tashiro T, Kawada Y, Sakurai Y, Kidani Y: Antitumor activity of a new platinum complex. Oxalato (trans-I-1,2-diaminocyclohexane)-platinum(II): New experimental data. Biomed Pharmacother 1989;43 251-260
42. Mathé G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, Ecstein E, Despax R, Musset M, Misset JL: A phase I trial of trans-I-diaminocyclohexane oxalato-platinum. Biomed Pharmacother 1986; 40:372-376
43. Raymond E, Djelloul S, Buquet-Fagot C, Goldwasser F, Mester J, Cvitkovic E, Louvet C, Gespach C Oxaliplatin (LOHP) and cisplatin (CDDP) in combination with 5FU, specific thymidylate synthase inhibitors (AG337, ZD1694), and topoisomerase I inhibitors (SN38, CPT-11), in human colonie, ovarian and breast cancer Proc Am Assoc Cancer Res 1996; 37:291(abstract 1981)
44. Belani CP, Lembersky B, Ramanathan R, Cohn A, Loh K, Miller W, Green M, Chew T, Johnston A, Clendeninn N: A phase II trial of Thymitaq™ (AG337) in patients with adenocarcinoma of the colon. Proc Am Soc Clin Oncol 1997;16:272a (abstract 965).
45. Cripps MC, Burnell M, Joliver J, Lofters W, Fisher B, Panasci L, Iglesias J, Eisenhauer E: Phase II study of a multi-targeted antifolate (LY231514) as first-line therapy in patients with locally advanced or metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997;16:267(abstract 949)
46. John W, Clark J, Burns H, Picus J, Schulman L, Thornton D, Lochrer P: A phase II trial of LY231514 in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997;16:292a(abstract 1038).
47. Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schornagel J, Adenis A, Green M, Iveson A, Azab A, Seymour I ZD1694, a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996;14:716-721.
48. Zalcberg JR, Ibrahim J, Johnston PG, Locker GY, O'Dwyer PJ, Weiner LM, Hochster HS, Rao S, Benson AB: ECOG phase II study of Tomudex® in advanced colorectal cancer. Proc Am Soc Clin Oncol 1997;16:268a(abstract 951).
49. Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G, Azab M, Seymour L, Lowery K: 'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995;31A:1945-1954.
50. Pazdur R, Vincent M: Raltitrexed (Tomudex®) versus 5-fluorouracil and leucovorin (5-FU+LV) in patients with advanced colorectal cancer: Results of a randomized, multicenter. North American trial. Proc Am Soc Clin Oncol 1997;16:228a(abstract 801)
51. Harper P: Advanced colorectal cancer: Results from the latest Tomudex® (raltitrexed) comparative study. Proc Am Soc Clin Oncol 1997;16:228a (abstract 802).
52. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-260
53. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA III, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer J Clin Oncol 1996;14:1128-1135.
54. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993;11:909-913.
55. Van Cutsem E, Cunningham D, Ten Bokkel Huinink W, Dirix L, Punt C, Alexopoulos C, Cote C, Blanc C, Bleiberg H: Irinotecan (CPT-11) multicenter phase II study in colorectal cancer patients with documented progressive disease on prior 5-FU: Preliminary results. Proc Am Soc Clin Oncol 1996; 5:230(abstract 562).
56. Pitot HC, Wender D, O'Connell MJ, Wieand HS, Mailliard JA: A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group (NCCTG) study Proc Am Soc Clin Oncol 1994;13:197(abstract 573).
57. Saltz L, Kemeny N, Soignet S, Quan V, Harrison J, Berkery R, Kelsen D: A phase II study of 9-aminocamptothecin in patients with fluorouracil-refractory colorectal cancer. Proc Am Soc Clin Oncol 1996;15 204(abstract 456)
58. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709-715.
59. Creemers GJ, Wanders J, Gamucci T, Vallentin S, Dirix LY, Schoffski P, Hudson I, Verweij J: Topotecan in colorectal cancer: A phase II study of the EORTC early clinical trials group Ann Oncol 1995;6:844-846.
60. Sugarman SM, Ajani JA, Daugherty K, Winn R, Lanzotti V, Bearden JD, Abbruzzese JL: A phase II trial of topotecan for the treatment of advanced measurable colorectal cancer. Proc Am Soc Clin Oncol 1994;13 225(abstract 686).
61. Creemers GJ, Gerrits CJH, Schellens JHM, Planting AST, van der Burg MEL, van Beurden VM, de Boer-Dennert M, Harteveld M, Loos W, Hudson I, Stoter G, Verweij J: Phase II and pharmocologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996;14:2540-2545.
62. Hochster H, Ibrahim J, Liebes L, O'Dwyer P, Benson A: Phase II study of 21-day topotecan continuous infusion for metastatic colorectal cancer (ECOG study 4293). Proc Am Soc Clin Oncol 1997;16:290a(abstract 1032).
63. Pitot C, Knost JA, Mahoney MR, O'Connell MJ, Krook J: A phase II trial of 9-amino-20(S) raltitrexed camptothecin (9-AC) in previously untreated patients with measurable metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 1997;16:303a (abstract 1077)
64. Van Cutsem E, Rougier Ph, Droz JP, Marty M, Bleiberg H Clinical benefit or irinofecan (CPT-11) in metastatic colorectal cancer resistant to 5-FU. Proc Am Soc Clin Oncol 1997;16:268a(abstract 950).
65. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-98.
66. Chacon RD, Coppola F, Mickiewicz E, Blajman C, Block J, Richardet E, Stagnaro A, Schmilovich A, Deza EG, Reale M: Expanded access program single agent oxaliplatin (L-OHP) in fluoropyrimidines resistant advanced colorectal cancer patients. Ann Oncol 1996,7(suppl 5) 39(abstract 180P)
67. Diaz-Rubio E, Zaniboni A, Gastiaburu J, Labianca R, Cortes-Funes H, De Braud F, Boni C, Vignoud J: Phase II multicentric trial of oxaliplatin (L-OHP) as first line chemotherapy in metastatic colorectal carcinoma Proc Am Soc Clin Oncol 1996;15:207 (abstract 468).
68. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Rougier P, Nguyen TD, Paillot B, Raoul JL, Fandi A: Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer patients: Preliminary activity/ toxicity report. Proc Am Soc Clin Oncol 1997;16: 229a(abstract 804).
69. Louvet C, Bleiberg H, Gamelin E, Francois E, André T, Extra JM, Nole F, Bensmaine MA, Itzhaki M, Brienza S, Cvitkovic E: Oxaliplatin (L-OHP) synergistic clinical activity with 5-fluorouracil (FU) in FU resistant colorectal cancer patients is independent of FU = folinic acid schedule. Proc Am Soc Clin Oncol 1996;15 206(abstract 467).
70. André T, Bensmaine MA, Louvet C, Lucas V, Beerblock K, Desseigne F, Francois E, Merrouche Y, Bouché O, Morvan F, Carola E, de Gramont A: Addition of oxaliplatin (Eloxatine®) to the same leucovorin and 5-fluorouracil bimonthly regimens after progression in patients with metastatic colorectal cancer. Preliminary report Proc Am Soc Clin Oncol 1997;16:270a(abstract 958).
71. Bertheault-Cvitkovic F, Jami A, Ithzaki M, Deprés Brummer P, Brienza S, Adam R, Kunstlinger F, Bismuth H, Misset JL, Lévi F: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and leucovorin in patients with metastatic colorectal cancer J. Clin Oncol 1996;14:2950-2958.
72. Lévi F, Dogliotti L, Perpoint B, Zidani R, Giacchetti S, Chollet P, Le Rol A, Llory JF, Focan C, Kunstlinger F, Adam R, Vannetzel JM, Letourneau Y, Jasmin C, Bismuth H, Misset JL: A multicenter phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil and folinic acid in patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997;16:266a (abstract 945).
73. Giacchetti S, Zidani R, Perpoint B, Pinel MC, Faggiuolo R, Focan C, Letourneau Y, Chollet P, Llory JF, Coudert B, Bertheault-Cvitkovic F, Adam R, Le Bail N, Misset JL, Bayssas M, Lévi F: Phase III trial of 5-fluorouracil, folinic acid, with or without oxaliplatin in previously untreated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997;16:229a(abstract 805).
74. Vanhoefer U, Harstrick A, Müller C, Achterrath W, Könne CH, Krauss C, Preusser PW, Wilke H, Seeber S: Phase I of a weekly schedule of irinotecan (CPT-11) in combination with high-dose folinic acid and 5-fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997;16:272a(abstract 967)
75. Van der Wilt CL, Pinedo HM, Kuiper CM, Smid K, Peters GJ: Biochemical basis for the combined antiproliferative effect of AG337 or ZD1694 and 5-fluorouracil. Proc Am Assoc Cancer Res 1995;36:379(abstract 2260).
76. Schmoll JH, Büchele T, Schober C: The role of second-line chemotherapy in colorectal cancer Onkologie 1997;20:288-294